SCM
INDV icon

Stonepine Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Stonepine Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1M Buy
+100,000
New +$3.63M 2.31% 13
2026
Q1 		– Sell
-100,000
Closed -$3.59M – 92
2025
Q4 		$3.59M Hold
100,000
– – 2.62% 8
2025
Q3 		$2.41M Sell
100,000
-250,000
-71% -$5.23M 1.96% 14
2025
Q2 		$5.16M Buy
350,000
+46,000
+15% +$536K 5.06% 5
2025
Q1 		$2.9M Sell
304,000
-1,000
-0.3% -$10.5K 2.82% 12
2024
Q4 		$3.79M Buy
305,000
+35,000
+13% +$360K 3.06% 10
2024
Q3 		$2.63M Buy
+270,000
New +$3.16M 1.66% 21

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stonepine Capital Management's INDV Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 100,000 shares worth $4.1M. The stake represents 2.31% of the portfolio and ranks #13 among its holdings. This is a return to the name: Stonepine Capital Management previously reported a position in INDV as recently as Q4 2025.

Stonepine Capital Management first reported a position in INDV in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.16M in Q2 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Stonepine Capital Management held 100,000 shares of Indivior Pharmaceuticals worth $4.1M as of Q2 2026.
  • Indivior Pharmaceuticals was a new Stonepine Capital Management position in Q2 2026.
  • Indivior Pharmaceuticals made up 2.31% of Stonepine Capital Management's portfolio in Q2 2026, its #13 holding.
  • Stonepine Capital Management first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Stonepine Capital Management's Indivior Pharmaceuticals position peaked at $5.16M in Q2 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.